# COSMIC-312 (NCT03755791)

> Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03755791
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Exelixis
- Conditions: Hepatocellular Carcinoma
- Interventions: Cabozantinib; Cabozantinib; Sorafenib; Atezolizumab
- Enrollment: 837
- Primary outcome: Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Population
- Primary outcome: Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Population

## Commentary we found

- X threads: 13
- Podcasts: 11
- YouTube: 7

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=cosmic-312-nct03755791

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03755791", "email": "<work email>"}; the inbox owner confirms by the emailed link.